Liu Y, Huang S, Kuang M, et al. - To clarify the expression of LARGE1 as well as its clinical significance in NSCLC, researchers used data from the TCGA database. They examined LARGE1 expression in stage I–III NSCLC as well as its links with clinicopathological parameters and overall survival. External cohorts from the NCBI GEO database were used to validate the findings. Abnormal downregulation of LARGE1 was found in NSCLC vs adjacent tissues and normal lung tissues and in advanced stage tumors with vs early stage tumors. In multivariate analysis, only a trend of a connection was seen between high LARGE1 and OS, though a significant link of high LARGE1 with improved OS was found in a subgroup of patients with adjuvant chemotherapy (ACT); there was a significant interaction between LARGE1 expression and ACT. Patients with high LARGE1, vs those with low LARGE1, had improved OS following ACT. In Gene Set Enrichment Analysis, the possibility of downregulation of cell cycle pathway by LARGE1 to improve ACT sensitivity and subsequently the prognosis in NSCLC was indicated. Overall, experts concluded that cases with resected stage I–III NSCLC that are most likely to benefit from adjuvant chemotherapy may be detected with high LARGE1.